Italy Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports

Italy Pharmaceuticals and Healthcare Report

Italy Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports
Italy Pharmaceuticals and Healthcare Report
Published Aug 20, 2016
83 pages — Published Aug 20, 2016
Price US$ 1,295.00  |  Buy this Report Now

About This Report

  
Abstract:

In ----, according to data published by OSMED, pharmaceutical spending in Italy amounted to EUR--.--bn (USD--.--bn), of which --.- was reimbursed by the SSN. On average, for every Italian citizen, spending on drugs amounted to about EUR---. ...Government spending accounts for a large proportion of pharmaceutical and healthcare spending and enforcing price cuts and controls on medicines seems a relatively easy way to rein in costs in the face of an escalating debt burden. Furthermore, while fiscal expenditure has continued to rise, this has not benefited the healthcare sector, as funds have been diverted towards bank bailouts, necessitating a subjective modification of the pharmaceutical forecast for Italy, particularly as our Pharmaceutical Expenditure Forecast Model uses fiscal expenditure as a variable. The decline in pharmaceutical expenditure by the national health service, Servizio Sanitario Nazionale ...Furthermore, while fiscal expenditure has continued to rise, this has not benefited the healthcare sector, as funds have been diverted towards bank bailouts, necessitating a subjective modification of the pharmaceutical forecast for Italy, particularly as our Pharmaceutical Expenditure Forecast Model uses fiscal expenditure as a variable. The decline in pharmaceutical expenditure by the national health service, Servizio Sanitario Nazionale

...BMI View: Prescription drugmakers operating in Italy will continue to face revenue challenges as spending by the country s national healthcare service, Servizio Sanitario Nazionale (SSN), continues to be restricted. The government remains committed to remaining under the - of GDP budget deficit limit and using any additional fiscal capacity to ease the tax burden instead of ramping up spending. ...BMI View: Prescription drugmakers operating in Italy will continue to face revenue challenges as spending by the country s national healthcare service, Servizio Sanitario Nazionale (SSN), continues to be restricted. The government remains committed to remaining under the - of GDP budget deficit limit and using any additional fiscal capacity to ease the tax burden instead of ramping up spending. This will continue to negatively impact the healthcare sector and particularly pharmaceutical spending, a large beneficiary of public funds. ...The government remains committed to remaining under the - of GDP budget deficit limit and using any additional fiscal capacity to ease the tax burden instead of ramping up spending. This will continue to negatively impact the healthcare sector and particularly pharmaceutical spending, a large beneficiary of public funds.

...All information contained in this publication is copyrighted in the name of Business Monitor International Ltd, and as such no part of this publication may be reproduced, repackaged, redistributed, resold in whole or in any part, or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping, or by information storage or retrieval, or by any other means, without the express written consent of the publisher. ...

...

  
Source:
Document ID
1748-8826
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Business Monitor International - Industry Reports—Established in 1984, Business Monitor International is a leading online publisher of specialist business information on global emerging markets. Business Monitor's range of quarterly services covers political risk, finance, macroeconomic performance, outlook and forecast, industry sectors and the business operating environment. Each Industry Report has been researched at source, and features latest-available data covering production, sales, imports and exports; 5-year industry forecasts through end-2012; company rankings and competitive landscapes for multinational and local manufacturers and suppliers; and analysis of latest industry developments, trends and regulatory changes.

About the Author


Cite this Report

  
MLA:
Business Monitor International - Industry Reports. "Italy Pharmaceuticals and Healthcare Report" Aug 20, 2016. Alacra Store. Dec 10, 2016. <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Italy-Pharmaceuticals-and-Healthcare-Report-2026-291>
  
APA:
Business Monitor International - Industry Reports. (2016). Italy Pharmaceuticals and Healthcare Report Aug 20, 2016. New York, NY: Alacra Store. Retrieved Dec 10, 2016 from <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Italy-Pharmaceuticals-and-Healthcare-Report-2026-291>
  
US$ 1,295.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.